$OGEN
ORAGENICS INC

2017 Q3 Form 10-Q Financial Statement

#000119312517257247 Filed on August 14, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2017 Q2 2016 Q4
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $930.0K $790.0K $930.0K
YoY Change -15.45% -14.2% 9.41%
% of Gross Profit
Research & Development $996.5K $605.4K $1.780M
YoY Change 7.75% -23.63% 32.84%
% of Gross Profit
Depreciation & Amortization $10.00K $20.00K $20.00K
YoY Change -50.0% 0.0% 0.0%
% of Gross Profit
Operating Expenses $1.922M $1.397M $2.708M
YoY Change -5.19% -19.42% 23.32%
Operating Profit -$1.922M -$1.397M -$2.708M
YoY Change -5.19% -19.42% 23.32%
Interest Expense $105.9K $57.87K $20.00K
YoY Change 8102.48% 6438.42% -200.0%
% of Operating Profit
Other Income/Expense, Net -$145.7K $175.8K $10.00K
YoY Change -790.67% -62875.71%
Pretax Income -$2.067M -$1.221M -$2.680M
YoY Change 3.07% -29.57% 20.72%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.067M -$1.221M -$2.675M
YoY Change 5.31% 290.53% 20.52%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$419.9K -$247.5K -$542.7K
COMMON SHARES
Basic Shares Outstanding 49.27M shares 49.27M shares 49.11M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q3 2017 Q2 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.920M $2.090M $4.080M
YoY Change -42.97% -61.72% -19.69%
Cash & Equivalents $2.923M $2.089M $4.081M
Short-Term Investments
Other Short-Term Assets $2.180M $2.440M $140.0K
YoY Change 1182.35% 1933.33% -33.33%
Inventory $0.00
Prepaid Expenses
Receivables $0.00
Other Receivables
Total Short-Term Assets $5.101M $4.526M $4.222M
YoY Change -3.54% -24.98% -25.12%
LONG-TERM ASSETS
Property, Plant & Equipment $34.12K $51.76K $87.46K
YoY Change -68.14% -50.32% -37.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $34.12K $51.76K $87.46K
YoY Change -68.14% -50.32% -37.82%
TOTAL ASSETS
Total Short-Term Assets $5.101M $4.526M $4.222M
Total Long-Term Assets $34.12K $51.76K $87.46K
Total Assets $5.135M $4.577M $4.309M
YoY Change -4.82% -25.41% -25.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.590M $1.060M $1.280M
YoY Change 101.27% 53.62% 31.96%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $130.0K $20.00K $70.00K
YoY Change 18.18% -33.33% 16.67%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.722M $1.084M $1.343M
YoY Change 89.42% 20.68% 28.27%
LONG-TERM LIABILITIES
Long-Term Debt $2.400M $2.400M $0.00
YoY Change
Other Long-Term Liabilities $590.0K
YoY Change
Total Long-Term Liabilities $2.400M $2.988M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.722M $1.084M $1.343M
Total Long-Term Liabilities $2.400M $2.988M $0.00
Total Liabilities $4.122M $4.072M $1.340M
YoY Change 353.0% 352.44% 27.62%
SHAREHOLDERS EQUITY
Retained Earnings -$99.94M -$97.87M -$94.67M
YoY Change 8.64% 8.71% 8.0%
Common Stock $49.27K $97.90M $97.62M
YoY Change -99.95% 0.64% 5.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.013M $505.5K $2.966M
YoY Change
Total Liabilities & Shareholders Equity $5.135M $4.577M $4.309M
YoY Change -4.82% -25.41% -25.43%

Cashflow Statement

Concept 2017 Q3 2017 Q2 2016 Q4
OPERATING ACTIVITIES
Net Income -$2.067M -$1.221M -$2.675M
YoY Change 5.31% 290.53% 20.52%
Depreciation, Depletion And Amortization $10.00K $20.00K $20.00K
YoY Change -50.0% 0.0% 0.0%
Cash From Operating Activities -$1.340M -$1.770M -$1.980M
YoY Change -21.64% 0.57% 23.75%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.180M 1.670M 940.0K
YoY Change 129.47% -35.52% -1980.0%
NET CHANGE
Cash From Operating Activities -1.340M -1.770M -1.980M
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 2.180M 1.670M 940.0K
Net Change In Cash 840.0K -100.0K -1.040M
YoY Change -354.55% -104.81% -36.97%
FREE CASH FLOW
Cash From Operating Activities -$1.340M -$1.770M -$1.980M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$1.340M -$1.980M
YoY Change -20.24% 23.75%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
49274219 shares
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5457444
CY2017Q2 us-gaap Assets Current
AssetsCurrent
4525683
CY2017Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
97846842
CY2017Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1060947
CY2017Q2 us-gaap Assets
Assets
4577438
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2088926
CY2017Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
3757956
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49274219 shares
CY2017Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4796621 shares
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49274219 shares
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
49274
CY2017Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
588437
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4577438
CY2017Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2988437
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1083508
CY2017Q2 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
2400000
CY2017Q2 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
CY2017Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2017Q2 us-gaap Preferred Stock Value
PreferredStockValue
482211
CY2017Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
517727
CY2017Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
51755
CY2017Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
1919030
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-97872834
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
505493
CY2017Q2 us-gaap Short Term Non Bank Loans And Notes Payable
ShortTermNonBankLoansAndNotesPayable
22561
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5083355
CY2015Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
175584 shares
CY2016Q4 us-gaap Assets Current
AssetsCurrent
4221704
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
97616444
CY2016Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1277066
CY2016Q4 us-gaap Assets
Assets
4309166
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4080618
CY2016Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
3830618
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49114219 shares
CY2016Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
175584 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49114219 shares
CY2016Q4 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
30563
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
49114
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4309166
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1343443
CY2016Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
141086
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
87462
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-94669272
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
2965723
CY2016Q4 us-gaap Short Term Non Bank Loans And Notes Payable
ShortTermNonBankLoansAndNotesPayable
66377
CY2017Q2 ogen Number Of Accredited Investors
NumberOfAccreditedInvestors
3 Investor
dei Amendment Flag
AmendmentFlag
false
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b>Concentrations</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> In June of 2016, the Company sold its consumer probiotics business, as such the Company is no longer dependent on key suppliers to continue to operate the consumer probiotics business.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents. As of June&#xA0;30, 2017, the uninsured portion of this balance was $3,757,956. As of December&#xA0;31, 2016, the uninsured portion of this balance was $3,830,618.</p> </div>
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1991692
us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2400
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Depreciation And Amortization
DepreciationAndAmortization
35707
us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
0
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-216119
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-3203562
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2017-06-30
dei Entity Registrant Name
EntityRegistrantName
ORAGENICS INC
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
294766
dei Entity Central Index Key
EntityCentralIndexKey
0001174940
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
231644
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1656543
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3203562
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.07
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
344656
us-gaap Interest Expense
InterestExpense
58666
us-gaap Investment Income Interest
InvestmentIncomeInterest
3767
us-gaap Interest Paid
InterestPaid
1605
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>1. Organization</b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Oragenics, Inc. (formerly known as Oragen, Inc.) (the &#x201C;Company&#x201D; or &#x201C;we&#x201D;) was incorporated in November, 1996; however, operating activity did not commence until 1999. We are focused on becoming a leader in developing novel antibiotics against infectious disease and on developing effective treatments for oral mucositis.</p> </div>
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1673816
us-gaap Operating Expenses
OperatingExpenses
3384415
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3665508
us-gaap Net Income Loss
NetIncomeLoss
-3203562
us-gaap Notes Assumed1
NotesAssumed1
31985
us-gaap Operating Income Loss
OperatingIncomeLoss
-3384415
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
180853
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6508
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Reclassification of Prior Period Presentation</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.</p> </div>
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
2400000
us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
-75801
us-gaap Profit Loss
ProfitLoss
-3203562
us-gaap Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
-1919030
us-gaap Restricted Stock Expense
RestrictedStockExpense
93828
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1727872
us-gaap Revenues
Revenues
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.36
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1056000 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
386666 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
200938
dei Trading Symbol
TradingSymbol
OGEN
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49232021 shares
us-gaap Unrealized Gain Loss On Derivatives And Commodity Contracts
UnrealizedGainLossOnDerivativesAndCommodityContracts
231644
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with US&#xA0;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The principal areas of estimation reflected in the financial statements are anticipated milestone payments, stock based compensation, valuation of warrants, and income tax valuation allowance. Inventory obsolescence reserve, sales returns and allowances and the allowance for doubtful accounts were the principal areas of estimation that had been reflected in the financial statements related to discontinued operations.</p> </div>
ogen Proceeds From Payment Of Stock Subscription Receivable
ProceedsFromPaymentOfStockSubscriptionReceivable
30563
ogen Par Value Of Restricted Shares Issued
ParValueOfRestrictedSharesIssued
160
ogen Class Of Warrant Granted In Period
ClassOfWarrantGrantedInPeriod
4621037 shares
ogen Class Of Warrant Expired
ClassOfWarrantExpired
0 shares
ogen Class Of Warrant Exercised
ClassOfWarrantExercised
0 shares
ogen Proceeds From Issuance Of Convertible Preferred Stock And Warrants
ProceedsFromIssuanceOfConvertiblePreferredStockAndWarrants
1238084
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
101749
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
272340
us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2378
us-gaap Depreciation And Amortization
DepreciationAndAmortization
36465
us-gaap Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax
DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
1453744
us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
0
us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
-21684
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
243565
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1790430
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3807560
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
1432060
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.10
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0.04
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-137487
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-3807560
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-146863
us-gaap Interest Expense
InterestExpense
1656
us-gaap Investment Income Interest
InvestmentIncomeInterest
4028
us-gaap Interest Paid
InterestPaid
885
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1250000
us-gaap Notes Issued1
NotesIssued1
450000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2562177
us-gaap Operating Expenses
OperatingExpenses
3807927
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3539837
us-gaap Net Income Loss
NetIncomeLoss
-2375500
us-gaap Notes Assumed1
NotesAssumed1
49395
us-gaap Operating Income Loss
OperatingIncomeLoss
-3807927
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
367
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
373
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
1250000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2640146
us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
-77969
us-gaap Profit Loss
ProfitLoss
-2375500
us-gaap Restricted Stock Expense
RestrictedStockExpense
84000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2017497
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.72
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
700000 shares
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
159566
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40010518 shares
ogen Par Value Of Restricted Shares Forfeited
ParValueOfRestrictedSharesForfeited
20
ogen Notes Issued For Stock
NotesIssuedForStock
2000000
ogen Par Value Of Restricted Shares Issued
ParValueOfRestrictedSharesIssued
230
CY2016 ogen Class Of Warrant Expired
ClassOfWarrantExpired
0 shares
CY2016 ogen Class Of Warrant Exercised
ClassOfWarrantExercised
0 shares
CY2016Q2 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1200
CY2016Q2 us-gaap Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax
DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
1453744
CY2016Q2 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
0
CY2016Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
-32797
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2016Q2 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
37804
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
940585
CY2016Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1733562
CY2016Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
1420947
CY2016Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.04
CY2016Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-1733562
CY2016Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0.04
CY2016Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016Q2 us-gaap Interest Expense
InterestExpense
885
CY2016Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1432
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
1733282
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-312615
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1733282
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-280
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
373
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
792697
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.58
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
300000 shares
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40065793 shares
CY2017Q2 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1200
CY2017Q2 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
0
CY2017Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
121
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2017Q2 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
122748
CY2017Q2 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
231644
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
791348
CY2017Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1220987
CY2017Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
121
CY2017Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.02
CY2017Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-1220987
CY2017Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0.00
CY2017Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017Q2 us-gaap Interest Expense
InterestExpense
57865
CY2017Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1832
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
1396759
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-1220866
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1396759
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
175772
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1361
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
605411
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.36
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1056000 shares
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49274219 shares

Files In Submission

Name View Source Status
0001193125-17-257247-index-headers.html Edgar Link pending
0001193125-17-257247-index.html Edgar Link pending
0001193125-17-257247.txt Edgar Link pending
0001193125-17-257247-xbrl.zip Edgar Link pending
d423255d10q.htm Edgar Link pending
d423255dex311.htm Edgar Link pending
d423255dex312.htm Edgar Link pending
d423255dex321.htm Edgar Link pending
d423255dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
ogen-20170630.xml Edgar Link completed
ogen-20170630.xsd Edgar Link pending
ogen-20170630_cal.xml Edgar Link unprocessable
ogen-20170630_def.xml Edgar Link unprocessable
ogen-20170630_lab.xml Edgar Link unprocessable
ogen-20170630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending